Premium
Hypolipidemic effects of clofibrate and selected chroman analogs in fasted rats: I. Chow‐fed animals
Author(s) -
O'Brien M.,
Patel S. T.,
Mukhopadhyay A.,
Newman H. A. I.,
Feller D. R.,
Kokrady S. S.,
Witiak D. T.,
Lanese R. R.,
Rice J. C.
Publication year - 1981
Publication title -
lipids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 120
eISSN - 1558-9307
pISSN - 0024-4201
DOI - 10.1007/bf02534996
Subject(s) - clofibrate , chemistry , medicine , endocrinology , clinical chemistry , microsome , cholesterol , carboxylate , lipidology , reductase , enzyme , biochemistry , biology
The hypolipidemic properties of ethyl 6‐chlorochroman‐2‐carboxylate (II), ethyl 6‐phenylchroman‐2‐carboxylate (III) and ethyl 6‐cyclohexylchroman‐2‐carboxylate (IV) were compared to clofibrate (I) in fasted normolipidemic rats. The chroman analog II, like its parent compound, clofibrate, reduced serum and α‐lipoprotein cholesterol concentrations. Although analog III had no effect on serum cholesterol, it caused a slight elevation of α‐lipoprotein cholesterol concentration. Serum free cholesterol was increased and LCAT activity was reduced in clofibrate‐treated rats. The hypolipidemic agents had no consistent effect on liver lipid concentrations and liver microsomal HMG‐CoA reductase activity. In addition, we have shown that drug efficacies varied directly with seasonal variations in serum lipid concentrations.